文献速递会诊联络精神医学心境障碍

抑郁治疗能否改善癌症抑郁患者生存?SMaRT Oncology-2和3试验长期随访

Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials.
PubMed 文献 · Lancet Psychiatry · 2018-03-12

本研究基于SMaRT Oncology-2和3两项随机试验的长期随访数据,分析抑郁治疗项目DCPC对癌症共病重性抑郁患者生存的影响。

核心结论

  • DCPC能有效改善癌症患者的抑郁和生活质量,但无证据表明对生存有显著影响。
  • 尽管对寿命无影响,抑郁管理对生活质量的益处仍使其具有重要意义。

研究设计与样本

  • 基于SMaRT Oncology-2和3两项随机对照试验的长期随访分析,试验在苏格兰三家癌症中心及其附属诊所开展。
  • SMaRT Oncology-2纳入预后良好癌症门诊患者500例,SMaRT Oncology-3纳入肺癌门诊患者142例,均按1:1随机分配至DCPC或常规照护。
  • 获取截至2015年7月31日的全因死亡长期数据,采用Cox回归估计未调整HR,并用固定效应荟萃分析合并log HR。

主要发现

  • SMaRT Oncology-2中位随访5年,500例中135例(27%)死亡;SMaRT Oncology-3中位随访1年,142例中114例(80%)死亡。

临床怎么用

  • DCPC可作为改善癌症共病抑郁患者抑郁症状和生活质量的有效手段。
  • 不应将延长生存作为抑郁治疗的主要预期获益依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comorbid major depression has been associated with worse survival in patients with cancer. However, we do not know if treating depression improves survival. In the SMaRT Oncology-2 (good prognosis cancers) and SMaRT Oncology-3 (lung cancer, a poor prognosis cancer) trials, we found that a depression treatment programme, Depression Care for People with Cancer (DCPC), was effective in reducing comorbid major depression. In this analysis, we aimed to identify whether DCPC also had an effect on survival. METHODS: The trials were conducted in three cancer centres and their associated clinics in Scotland, UK. In SMaRT Oncology-2, outpatients with good prognosis cancers and major depression were randomly assigned in a 1:1 ratio to DCPC or usual care, with stratification (by trial centre) and minimisation (by age, primary cancer, and sex) with allocation concealment. In SMaRT Oncology-3, outpatients with lung cancer and major depression were randomly assigned (1:1 ratio) to DCPC or usual care with stratification (by trial centre) and minimisation (by age, sex, and cancer type) with allocation concealment. For this analysis, we obtained long-term data on deaths (all causes) in the SMaRT Oncology-2 and 3 trial participants, censored at July 31, 2015, and analysed survival as a trial outcome. We estimated unadjusted hazard ratios (HRs) for each trial using Cox regression, and pooled the log HRs in a fixed-effects meta-analysis. FINDINGS: We recruited 642 participants; between May 12, 2008, and May 13, 2011, 500 participants were recruited to the SMaRT Oncology-2 trial and between Jan 5, 2009, and Sept 9, 2011, 142 participants were recruited to the SMaRT Oncology-3 trial. We followed up SMaRT Oncology-2 and SMaRT Oncology-3 participants for a median of 5 years and 1 year, respectively. 135 (27%) of 500 SMaRT Oncology-2 participants and 114 (80%) of 142 SMaRT Oncology-3 participants died within this period. We found no significant effect of DCPC on survival in the total follow-up period for either SMaRT Oncology 2 (HR 1·02, 95% CI 0·72-1·42, p=0·93) or SMaRT Oncology-3 (HR 0·82, 95% CI 0·56-1·18, p=0·28; pooled HR 0·92, 95% CI 0·72-1·18, p=0·51). INTERPRETATION: DCPC is highly effective in improving depression and quality of life in depressed patients with cancer, but there was no evidence for a significant effect on survival. Despite the absence of an effect on length of life, the management of depression remains important for its beneficial effect on quality of life. FUNDING: NIHR CLAHRC Oxford, Cancer Research UK, and the Chief Scientist Office of the Scottish Government.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mulick A, Walker J, Puntis S, et al. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Lancet Psychiatry. 2018. PMID: 29544711. doi:10.1016/S2215-0366(18)30061-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。